NovaBay Pharmaceuticals (NYSE-A:NBY) CEO Justin Hall joined Steve Darling from Proactive to talk more about the company that has developed scientifically proven eye care, skincare and wound care products. The company top product is Avenova which has proven in laboratory testing to have broad antimicrobial properties as it removes foreign material and debris from the skin around the eye, including the eyelid. Hall telling Proactive the company acquired DermaDoctor, a skincare brand, in 2021. Hall emphasizes that all their products are doctor-recommended and clinically developed to address specific needs. NovaBay aims to excel in all three verticals, which includes wound care and expects continued growth and success.
NovaBay Pharmaceuticals looking to grow its three verticals, eye, skin, and wound care in 2023
